{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:21:07Z","timestamp":1782937267691,"version":"3.54.5"},"reference-count":91,"publisher":"National Institute for Health and Care Research","issue":"75","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["09\/144\/09"],"award-info":[{"award-number":["09\/144\/09"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Levetiracetam (Keppra\u00ae<\/jats:sup>, UCB Pharma Ltd, Slough, UK) and zonisamide (Zonegran\u00ae<\/jats:sup>, Eisai Co. Ltd, Tokyo, Japan) are licensed as monotherapy for focal epilepsy, and levetiracetam is increasingly used as a first-line treatment for generalised epilepsy, particularly for women of childbearing age. However, there is uncertainty as to whether or not they should be recommended as first-line treatments owing to a lack of evidence of clinical effectiveness and cost-effectiveness.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To compare the clinical effectiveness and cost-effectiveness of lamotrigine (Lamictal\u00ae<\/jats:sup>, GlaxoSmithKline plc, Brentford, UK) (standard treatment) with levetiracetam and zonisamide (new treatments) for focal epilepsy, and to compare valproate (Epilim\u00ae<\/jats:sup>, Sanofi SA, Paris, France) (standard treatment) with levetiracetam (new treatment) for generalised and unclassified epilepsy.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Two pragmatic randomised unblinded non-inferiority trials run in parallel.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Outpatient services in NHS hospitals throughout the UK.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Those aged \u2265\u20095 years with two or more spontaneous seizures that require anti-seizure medication.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants with focal epilepsy were randomised to receive lamotrigine, levetiracetam or zonisamide. Participants with generalised or unclassifiable epilepsy were randomised to receive valproate or levetiracetam. The randomisation method was minimisation using a web-based program.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n The primary outcome was time to 12-month remission from seizures. For this outcome, and all other time-to-event outcomes, we report hazard ratios for the standard treatment compared with the new treatment. For the focal epilepsy trial, the non-inferiority limit (lamotrigine vs. new treatments) was 1.329. For the generalised and unclassified epilepsy trial, the non-inferiority limit (valproate vs. new treatments) was 1.314. Secondary outcomes included time to treatment failure, time to first seizure, time to 24-month remission, adverse reactions, quality of life and cost-effectiveness.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Focal epilepsy<\/jats:italic>. A total of 990 participants were recruited, of whom 330 were randomised to receive lamotrigine, 332 were randomised to receive levetiracetam and 328 were randomised to receive zonisamide. Levetiracetam did not meet the criteria for non-inferiority (hazard ratio 1.329) in the primary intention-to-treat analysis of time to 12-month remission (hazard ratio vs. lamotrigine 1.18, 97.5% confidence interval 0.95 to 1.47), but zonisamide did meet the criteria (hazard ratio vs. lamotrigine 1.03, 97.5% confidence interval 0.83 to 1.28). In the per-protocol analysis, lamotrigine was superior to both levetiracetam (hazard ratio 1.32, 95% confidence interval 1.05 to 1.66) and zonisamide (hazard ratio 1.37, 95% confidence interval 1.08 to 1.73). For time to treatment failure, lamotrigine was superior to levetiracetam (hazard ratio 0.60, 95% confidence interval 0.46 to 0.77) and zonisamide (hazard ratio 0.46, 95% confidence interval 0.36 to 0.60). Adverse reactions were reported by 33% of participants starting lamotrigine, 44% starting levetiracetam and 45% starting zonisamide. In the economic analysis, both levetiracetam and zonisamide were more costly and less effective than lamotrigine and were therefore dominated. Generalised and unclassifiable epilepsy<\/jats:italic>. Of 520 patients recruited, 260 were randomised to receive valproate and 260 were randomised to receive to levetiracetam. A total of 397 patients had generalised epilepsy and 123 had unclassified epilepsy. Levetiracetam did not meet the criteria for non-inferiority in the primary intention-to-treat analysis of time to 12-month remission (hazard ratio 1.19, 95% confidence interval 0.96 to 1.47; non-inferiority margin 1.314). In the per-protocol analysis of time to 12-month remission, valproate was superior to levetiracetam (hazard ratio 1.68, 95% confidence interval 1.30 to 2.15). Valproate was superior to levetiracetam for time to treatment failure (hazard ratio 0.65, 95% confidence interval 0.50 to 0.83). Adverse reactions were reported by 37.4% of participants receiving valproate and 41.5% of those receiving levetiracetam. Levetiracetam was both more costly (incremental cost of \u00a3104, 95% central range \u2013\u00a3587 to \u00a31234) and less effective (incremental quality-adjusted life-year of \u20130.035, 95% central range \u20130.137 to 0.032) than valproate, and was therefore dominated. At a cost-effectiveness threshold of \u00a320,000 per quality-adjusted life-year, levetiracetam was associated with a probability of 0.17 of being cost-effective.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n The SANAD II trial was unblinded, which could have biased results by influencing decisions about dosing, treatment failure and the attribution of adverse reactions.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n SANAD II data could now be included in an individual participant meta-analysis of similar trials, and future similar trials are required to assess the clinical effectiveness and cost-effectiveness of other new treatments, including lacosamide and perampanel.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Focal epilepsy<\/jats:italic> \u2013 The SANAD II findings do not support the use of levetiracetam or zonisamide as first-line treatments in focal epilepsy. Generalised and unclassifiable epilepsy<\/jats:italic> \u2013 The SANAD II findings do not support the use of levetiracetam as a first-line treatment for newly diagnosed generalised epilepsy. For women of childbearing potential, these results inform discussions about the benefit (lower teratogenicity) and harm (worse seizure outcomes and higher treatment failure rate) of levetiracetam compared with valproate.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n Current Controlled Trials ISRCTN30294119 and EudraCT 2012-001884-64.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment<\/jats:italic>; Vol. 25, No. 75. See the NIHR Journals Library website for further project information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta25750","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T12:31:51Z","timestamp":1640089911000},"page":"1-134","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs"],"prefix":"10.3310","volume":"25","clinical-trial-number":[{"clinical-trial-number":"isrctn30294119","registry":"10.18810\/isrctn","type":"results"},{"clinical-trial-number":"2012-001884-64","registry":"10.18810\/euctr","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-8806","authenticated-orcid":true,"given":"Anthony G","family":"Marson","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7398-1346","authenticated-orcid":true,"given":"Girvan","family":"Burnside","sequence":"additional","affiliation":[{"name":"Department of Health Data Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-2113","authenticated-orcid":true,"given":"Richard","family":"Appleton","sequence":"additional","affiliation":[{"name":"The Roald Dahl EEG Unit, Alder Hey Children\u2019s Health Park, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3449-4777","authenticated-orcid":true,"given":"Dave","family":"Smith","sequence":"additional","affiliation":[{"name":"The Walton Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-9937","authenticated-orcid":true,"given":"John Paul","family":"Leach","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-8713","authenticated-orcid":true,"given":"Graeme","family":"Sills","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3051-1445","authenticated-orcid":true,"given":"Catrin","family":"Tudur-Smith","sequence":"additional","affiliation":[{"name":"Department of Health Data Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2710-9199","authenticated-orcid":true,"given":"Catrin O","family":"Plumpton","sequence":"additional","affiliation":[{"name":"Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-7459","authenticated-orcid":true,"given":"Dyfrig A","family":"Hughes","sequence":"additional","affiliation":[{"name":"Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-6636","authenticated-orcid":true,"given":"Paula R","family":"Williamson","sequence":"additional","affiliation":[{"name":"Department of Health Data Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5736-605X","authenticated-orcid":true,"given":"Gus","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6989-8099","authenticated-orcid":true,"given":"Silviya","family":"Balabanova","sequence":"additional","affiliation":[{"name":"Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4746-9730","authenticated-orcid":true,"given":"Claire","family":"Taylor","sequence":"additional","affiliation":[{"name":"Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1591-3959","authenticated-orcid":true,"given":"Richard","family":"Brown","sequence":"additional","affiliation":[{"name":"Addenbrooke\u2019s Hospital NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4128-6995","authenticated-orcid":true,"given":"Dan","family":"Hindley","sequence":"additional","affiliation":[{"name":"Bolton NHS Foundation Trust, Royal Bolton Hospital, Bolton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8504-9644","authenticated-orcid":true,"given":"Stephen","family":"Howell","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-6743","authenticated-orcid":true,"given":"Melissa","family":"Maguire","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-148X","authenticated-orcid":true,"given":"Rajiv","family":"Mohanraj","sequence":"additional","affiliation":[{"name":"Salford Royal NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4250-2562","authenticated-orcid":true,"given":"Philip EM","family":"Smith","sequence":"additional","affiliation":[{"name":"The Alan Richens Epilepsy Unit, University Hospital of Wales, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2021,12]]},"reference":[{"key":"key20211220095046754_ref1-bib1","volume-title":"Epilepsy: Frequency, Causes and Consequences","author":"Hauser","year":"1990"},{"key":"key20211220095046754_ref1-bib2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"key":"key20211220095046754_ref1-bib3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"key":"key20211220095046754_ref1-bib4","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/j.1528-1167.2008.01819.x","article-title":"Labor market participation following onset of seizures and early epilepsy: findings from a UK cohort","volume":"50","author":"Holland","year":"2009","journal-title":"Epilepsia"},{"key":"key20211220095046754_ref1-bib5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1586\/14737175.6.1.111","article-title":"Quality of life for patients with epilepsy is determined by more than seizure control: the role of psychosocial factors","volume":"6","author":"Schachter","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"key20211220095046754_ref1-bib6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"key":"key20211220095046754_ref1-bib7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1474-4422(12)70018-2","article-title":"Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial","volume":"11","author":"Bonnett","year":"2012","journal-title":"Lancet Neurol"},{"key":"key20211220095046754_ref1-bib8","unstructured":"National Institute for Health and Care Excellence. Epilepsies: Diagnosis and Management. Clinical Guideline [CG137]. London: National Institute for Health and Care Excellence; 2012."},{"key":"key20211220095046754_ref1-bib9","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"key20211220095046754_ref1-bib10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1474-4422(05)70172-1","article-title":"Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study","volume":"4","author":"Olafsson","year":"2005","journal-title":"Lancet Neurol"},{"key":"key20211220095046754_ref1-bib11","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/j.1528-1157.1999.tb01587.x","article-title":"Incidence of epileptic syndromes in Rochester, Minnesota: 1980\u20131984","volume":"40","author":"Zarrelli","year":"1999","journal-title":"Epilepsia"},{"key":"key20211220095046754_ref1-bib12","unstructured":"National Institute for Health and Care Excellence. The Epilepsies: the Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care. Clinical Guideline [CG20]. London: National Institute for Health and Care Excellence; 2004."},{"key":"key20211220095046754_ref1-bib13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001030","article-title":"Carbamazepine versus valproate monotherapy for epilepsy","volume":"3","author":"Marson","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"key20211220095046754_ref1-bib14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001769","article-title":"Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic\u2013clonic seizures","volume":"4","author":"Tudur Smith","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"key20211220095046754_ref1-bib15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011412.pub2","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"6","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"key20211220095046754_ref1-bib16","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"key20211220095046754_ref1-bib17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa0902014","article-title":"Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy","volume":"362","author":"Glauser","year":"2010","journal-title":"N Engl J Med"},{"key":"key20211220095046754_ref1-bib18","volume-title":"New Measures to Avoid Valproate Exposure in Pregnancy Endorsed. Member State Representatives Agree New Restrictions and Pregnancy Prevention Programme","author":"European Medicines Agency","year":"2018"},{"key":"key20211220095046754_ref1-bib19","doi-asserted-by":"publisher","first-page":"e034829","DOI":"10.1136\/bmjopen-2019-034829","article-title":"Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study","volume":"10","author":"Bloti\u00e8re","year":"2020","journal-title":"BMJ Open"},{"key":"key20211220095046754_ref1-bib20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/WNL.0b013e31827f0874","article-title":"Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers","volume":"80","author":"Mawhinney","year":"2013","journal-title":"Neurology"},{"key":"key20211220095046754_ref1-bib21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"key20211220095046754_ref1-bib22","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/jnnp-2011-300376","article-title":"KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy","volume":"84","author":"Trinka","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20211220095046754_ref1-bib23","unstructured":"Joint Formulary Committee. British National Formulary. 60th ed. London: BMJ Group and Pharmaceutical Press; 2010."},{"key":"key20211220095046754_ref1-bib24","volume-title":"British National Formulary","author":"Joint Formulary Committee"},{"key":"key20211220095046754_ref1-bib25","doi-asserted-by":"publisher","first-page":"e032551","DOI":"10.1136\/bmjopen-2019-032551","article-title":"Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016: a retrospective cohort study using electronic medical records","volume":"9","author":"Powell","year":"2019","journal-title":"BMJ Open"},{"key":"key20211220095046754_ref1-bib26","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"key20211220095046754_ref1-bib27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"key20211220095046754_ref1-bib28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.seizure.2004.04.015","article-title":"Review of zonisamide development in Japan","volume":"13","author":"Seino","year":"2004","journal-title":"Seizure"},{"key":"key20211220095046754_ref1-bib29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1474-4422(12)70105-9","article-title":"Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"11","author":"Baulac","year":"2012","journal-title":"Lancet Neurol"},{"key":"key20211220095046754_ref1-bib30","doi-asserted-by":"publisher","first-page":"e040635","DOI":"10.1136\/bmjopen-2020-040635","article-title":"Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II)","volume":"10","author":"Balabanova","year":"2020","journal-title":"BMJ Open"},{"key":"key20211220095046754_ref1-bib31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0920-1211(93)90042-6","article-title":"Measuring the impact of epilepsy: the development of a novel scale","volume":"16","author":"Jacoby","year":"1993","journal-title":"Epilepsy Res"},{"key":"key20211220095046754_ref1-bib32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1023\/a:1008853819715","article-title":"Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results","volume":"7","author":"Ravens-Sieberer","year":"1998","journal-title":"Qual Life Res"},{"key":"key20211220095046754_ref1-bib33","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/j.1528-1157.1999.tb00828.x","article-title":"Development of the Quality of Life in Epilepsy Inventory for Adolescents: the QOLIE-AD-48","volume":"40","author":"Cramer","year":"1999","journal-title":"Epilepsia"},{"key":"key20211220095046754_ref1-bib34","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1542\/peds.2004-2127","article-title":"Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health","volume":"115","author":"Griebsch","year":"2005","journal-title":"Pediatrics"},{"key":"key20211220095046754_ref1-bib35","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/00019053-200725090-00001","article-title":"Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations","volume":"25","author":"Prosser","year":"2007","journal-title":"PharmacoEconomics"},{"key":"key20211220095046754_ref1-bib36","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1528-1157.2000.tb00317.x","article-title":"Patient-based assessments of quality of life in newly diagnosed epilepsy patients: validation of the NEWQOL","volume":"41","author":"Abetz","year":"2000","journal-title":"Epilepsia"},{"key":"key20211220095046754_ref1-bib37","first-page":"200","volume-title":"Measuring Mental Health Needs","author":"Beecham","year":"2001","edition":"2nd"},{"key":"key20211220095046754_ref1-bib38","volume-title":"User Guide: Reference Costs 2017\/18","author":"NHS Improvement","year":"2018"},{"key":"key20211220095046754_ref1-bib39","unstructured":"Joint Formulary Committee. British National Formulary. 77th ed. London: BMJ Group and Pharmaceutical Press; 2019."},{"key":"key20211220095046754_ref1-bib40","volume-title":"Unit Costs of Health and Social Care 2018","author":"Curtis","year":"2018"},{"key":"key20211220095046754_ref1-bib41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1528-1157.1998.tb01167.x","article-title":"Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy","volume":"39","author":"Chadwick","year":"1998","journal-title":"Epilepsia"},{"key":"key20211220095046754_ref1-bib42","doi-asserted-by":"publisher","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med"},{"key":"key20211220095046754_ref1-bib43","unstructured":"European Medicines Agency. Topic E 9 Statistical Principles for Clinical Trials (CPMP\/ICH\/363\/96). Geneva: International Conference on Harmonisation; 1998."},{"key":"key20211220095046754_ref1-bib44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"key20211220095046754_ref1-bib45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1745-6215-8-12","article-title":"Importance of competing risks in the analysis of anti-epileptic drug failure","volume":"8","author":"Williamson","year":"2007","journal-title":"Trials"},{"key":"key20211220095046754_ref1-bib46","volume-title":"Linear Mixed Models with Repeated Effects. Introduction and Examples Using SAS\/STAT\u00ae Software","author":"Davis","year":"2017"},{"key":"key20211220095046754_ref1-bib47","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1001\/jama.294.17.2228","article-title":"When (not) to stop a clinical trial for benefit","volume":"294","author":"Pocock","year":"2005","journal-title":"JAMA"},{"key":"key20211220095046754_ref1-bib48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) \u2013 explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"key20211220095046754_ref1-bib49","volume-title":"SANAD-II RUM","author":"Database of Instruments for Resource Use Management","year":"2015"},{"issue":"37","key":"key20211220095046754_ref1-bib50","doi-asserted-by":"publisher","DOI":"10.3310\/hta11370","article-title":"A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial","volume":"11","author":"Marson","year":"2007","journal-title":"Health Technol Assess"},{"key":"key20211220095046754_ref1-bib51","volume-title":"Data Linkage & Extract Service","author":"NHS Digital","year":"2021"},{"key":"key20211220095046754_ref1-bib52","volume-title":"The Secure Anonymised Information Linkage Databank","author":"SAIL Databank","year":"2021"},{"key":"key20211220095046754_ref1-bib53","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s41669-018-0068-1","article-title":"Which costs matter? Costs included in economic evaluation and their impact on decision uncertainty for stable coronary artery disease","volume":"2","author":"Lomas","year":"2018","journal-title":"PharmacoEcon Open"},{"key":"#cr-split#-key20211220095046754_ref1-bib54.1","unstructured":"Department of Health and Social Care. 2018\/19 National Cost Collection Data Publication. London: Department of Health and Social Care"},{"key":"#cr-split#-key20211220095046754_ref1-bib54.2","unstructured":"2021. URL: www.england.nhs.uk\/publication\/2018-19-national-cost-collection-data-publication\/ (accessed 16 September 2021)."},{"key":"key20211220095046754_ref1-bib55","volume-title":"Unit Costs of Health and Social Care 2019","author":"Curtis","year":"2019"},{"key":"key20211220095046754_ref1-bib56","volume-title":"Prescription Cost Analysis (PCA) Data September 2019","author":"NHS Business Services Authority","year":"2019"},{"key":"key20211220095046754_ref1-bib57","volume-title":"NHS Wales Data Dictionary","author":"NHS Wales","year":"2020"},{"key":"key20211220095046754_ref1-bib58","volume-title":"National Casemix Office HRG4+ 2018\/19 Payment Grouper","author":"NHS Digital","year":"2019"},{"key":"key20211220095046754_ref1-bib59","unstructured":"National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. London: National Institute for Health and Care Excellence; 2013."},{"key":"key20211220095046754_ref1-bib60","first-page":"191","volume-title":"Quality of Life and Pharmacoeconomics in Clinical Trials","author":"Kind","year":"1996","edition":"2nd"},{"key":"key20211220095046754_ref1-bib61","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.yebeh.2012.02.025","article-title":"The development of a QALY measure for epilepsy: NEWQOL-6D","volume":"24","author":"Mulhern","year":"2012","journal-title":"Epilepsy Behav"},{"key":"key20211220095046754_ref1-bib62","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"key20211220095046754_ref1-bib63","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s41669-017-0015-6","article-title":"Handling missing data in within-trial cost-effectiveness analysis: a review with future recommendations","volume":"1","author":"Gabrio","year":"2017","journal-title":"PharmacoEcon Open"},{"key":"key20211220095046754_ref1-bib64","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11121-007-0070-9","article-title":"How many imputations are really needed? Some practical clarifications of multiple imputation theory","volume":"8","author":"Graham","year":"2007","journal-title":"Prev Sci"},{"key":"key20211220095046754_ref1-bib65","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2165\/00019053-200927060-00007","article-title":"How to deal with cost differences at baseline","volume":"27","author":"van Asselt","year":"2009","journal-title":"PharmacoEconomics"},{"key":"key20211220095046754_ref1-bib66","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/hec.1653","article-title":"Review of statistical methods for analysing healthcare resources and costs","volume":"20","author":"Mihaylova","year":"2011","journal-title":"Health Econ"},{"key":"key20211220095046754_ref1-bib67","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40273-020-00914-6","article-title":"Calculating and interpreting ICERs and net benefit","volume":"38","author":"Paulden","year":"2020","journal-title":"PharmacoEconomics"},{"key":"key20211220095046754_ref1-bib68","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hec.635","article-title":"Representing uncertainty: the role of cost-effectiveness acceptability curves","volume":"10","author":"Fenwick","year":"2001","journal-title":"Health Econ"},{"key":"key20211220095046754_ref1-bib69","first-page":"12","article-title":"Directive 2001\/20\/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use","volume":"9","year":"2002","journal-title":"Med Etika Bioet"},{"key":"key20211220095046754_ref1-bib70","unstructured":"European Medicines Agency (EMA). Guideline for Good Clinical Practice E6(R2): Step 5. London: EMA; 2016."},{"key":"key20211220095046754_ref1-bib71","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"key20211220095046754_ref1-bib72","unstructured":"Health Research Authority (HRA). UK Policy Framework for Health and Social Care Research. London: HRA; 2017."},{"key":"key20211220095046754_ref1-bib73","unstructured":"Great Britain. The Medicines for Human Use (Clinical Trials) Regulations 2004. London: The Stationery Office; 2004."},{"key":"key20211220095046754_ref1-bib74","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide or lamotrigine for newly diagnosed focal epilepsy: an open label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"key20211220095046754_ref1-bib75","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jval.2020.02.011","article-title":"A review of the methods used to generate utility values in NICE technology assessments for children and adolescents","volume":"23","author":"Hill","year":"2020","journal-title":"Value Health"},{"key":"key20211220095046754_ref1-bib76","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40273-020-00909-3","article-title":"International valuation protocol for the EQ-5D-Y-3L","volume":"38","author":"Ramos-Go\u00f1i","year":"2020","journal-title":"PharmacoEconomics"},{"key":"key20211220095046754_ref1-bib77","volume-title":"Guideline on Clinical Investigation of Medicinal Products in the Treatment of Epileptic Disorders","author":"European Medicines Agency","year":"2010"},{"key":"key20211220095046754_ref1-bib78","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/epi4.12239","article-title":"From clinical trials of antiepileptic drugs to treatment","volume":"3","author":"Perucca","year":"2018","journal-title":"Epilepsia Open"},{"key":"key20211220095046754_ref1-bib79","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","author":"Nevitt","journal-title":"Cochrane Database Syst Rev"},{"key":"key20211220095046754_ref1-bib80","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jnnp.2005.074203","article-title":"Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register","volume":"77","author":"Morrow","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20211220095046754_ref1-bib81","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"key":"key20211220095046754_ref1-bib82","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet Neurol"},{"key":"key20211220095046754_ref1-bib83","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"key":"key20211220095046754_ref1-bib84","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/cpt.1231","article-title":"Patient-focused drug development methods for benefit-risk assessments: a case study using a discrete choice experiment for antiepileptic drugs","volume":"105","author":"Holmes","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"key20211220095046754_ref1-bib85","volume-title":"Unit Costs of Health and Social Care 2015","author":"Curtis","year":"2015"},{"key":"key20211220095046754_ref1-bib86","volume-title":"Out-of-Hours GP Services in England","author":"Department of Health and Social Care and NHS England","year":"2014"},{"key":"key20211220095046754_ref1-bib87","volume-title":"NHS Voucher Values for Glasses and Lenses","author":"NHS","year":"2020"},{"key":"key20211220095046754_ref1-bib88","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.jval.2017.04.012","article-title":"Evaluation of a stratified national breast screening program in the United Kingdom: an early model-based cost-effectiveness analysis","volume":"20","author":"Gray","year":"2017","journal-title":"Value Health"},{"key":"key20211220095046754_ref1-bib89","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1136\/ijgc-2018-000161","article-title":"Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England","volume":"29","author":"Bains","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"key20211220095046754_ref1-bib90","doi-asserted-by":"publisher","first-page":"e014815","DOI":"10.1136\/bmjopen-2016-014815","article-title":"Has the NHS 111 urgent care telephone service been a success? Case study and secondary data analysis in England","volume":"7","author":"Pope","year":"2017","journal-title":"BMJ Open"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta25750\/hta25750.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:38:56Z","timestamp":1692113936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta25750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":91,"journal-issue":{"issue":"75","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["10.3310\/hta25750"],"URL":"https:\/\/doi.org\/10.3310\/hta25750","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"6-2012","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"10-2020","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"8-2021","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}